Fluvoxamine Inhibited NLRP3 and NF‐κB Inflammatory Pathways and Maintained Genital Functions by Ameliorating CD‐MPR, KISS‐1, AQP4 and Claudin‐1 Expressions
Basic & Clinical Pharmacology & Toxicology · 2025
DOI: 10.1111/bcpt.70000 ↗Kurz gefasst
Fachartikel in der Zeitschrift Basic & Clinical Pharmacology & Toxicology, 2025. Verfasst von Senay Topsakal und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Metabolism, Faculty of Medicine, Pamukkale University, Denizli, Türkiye. Hauptthemen laut MEDLINE: Fluvoxamine, Selective Serotonin Reuptake Inhibitors, Genitalia, Female. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Suleyman Demirel University.
Abstract (Originalsprache)
Fluvoxamine (FLV), a selective serotonin reuptake inhibitor, is commonly used to treat anxiety, major depressive disorder and obsessive‐compulsive disorder, among other psychiatric conditions. This study aims to evaluate the effectiveness of FLV in mitigating damage caused by lipopolysaccharide (LPS) to the female genital tract. Thirty‐two female Wistar Albino rats were randomly divided into four groups: control, LPS, LPS‐FLV and FLV. At the end of the experimental period, tissues from the ovaries, fallopian tubes and uterus were collected for histological, immunohistochemical and genetic analyses. Histological examination of the LPS group revealed mild to moderate bleeding, oedema and neutrophil infiltration. Additionally, there were signs of endometrial damage in the uterus and loss of cilia in the fallopian tubes. Immunohistochemical analysis showed that LPS increased the expressions of nuclear factor kappa beta (NF‐κB) and cation‐dependent mannose 6‐phosphate receptors (CD‐MPR) and reduced kisspeptin‐1 (KISS‐1) expression. Genetic analysis indicated that LPS increased the expression of the NOD‐like receptor family pyrin domain‐containing 3 (NLRP3) and aquaporin4 (AQP4) genes while decreasing Claudin‐1 expression. However, all these adverse effects were reversed by FLV treatment. The study's findings suggest that FLV may be beneficial in treating LPS‐induced damage to the female reproductive system.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology and Metabolism, Faculty of Medicine, Pamukkale University, Denizli, Türkiye.
- Department of Pathology, Faculty of Veterinary Medicine, Burdur Mehmet Akif Ersoy University, Burdur, Türkiye.
- Department of Gynecology and Obstetrics, Faculty of Medicine, Suleyman Demirel University, Isparta, Türkiye.
- Department of Pharmacology, Faculty of Medicine, Suleyman Demirel University, Isparta, Türkiye.
- Department of Medical Biology, Faculty of Medicine, Suleyman Demirel University, Isparta, Türkiye.
ORCID-Profile: Senay Topsakal, Ozlem Ozmen, Kadriye Nilay Ozcan, Halil Asci, Orhan Berk Imeci, Mehmet Abdulkadir Sevuk, Pinar Aslan Kosar
Förderung
- Suleyman Demirel University
Zitieren
APA
Topsakal, S., Ozmen, O., Ozcan, K. N., Asci, H., Imeci, O. B., Sevuk, M. A., & Kosar, P. A. (2025). Fluvoxamine Inhibited NLRP3 and NF‐κB Inflammatory Pathways and Maintained Genital Functions by Ameliorating CD‐MPR, KISS‐1, AQP4 and Claudin‐1 Expressions. Basic & Clinical Pharmacology & Toxicology. https://doi.org/10.1111/bcpt.70000
Vancouver
Topsakal S, Ozmen O, Ozcan KN, Asci H, Imeci OB, Sevuk MA, et al. Fluvoxamine Inhibited NLRP3 and NF‐κB Inflammatory Pathways and Maintained Genital Functions by Ameliorating CD‐MPR, KISS‐1, AQP4 and Claudin‐1 Expressions. Basic & Clinical Pharmacology & Toxicology. 2025. doi:10.1111/bcpt.70000
BibTeX
@article{Topsakal2025,
author = {Topsakal, Senay and Ozmen, Ozlem and Ozcan, Kadriye Nilay and Asci, Halil and Imeci, Orhan Berk and Sevuk, Mehmet Abdulkadir and Kosar, Pinar Aslan},
title = {Fluvoxamine Inhibited NLRP3 and NF‐κB Inflammatory Pathways and Maintained Genital Functions by Ameliorating CD‐MPR, KISS‐1, AQP4 and Claudin‐1 Expressions},
journal = {Basic & Clinical Pharmacology & Toxicology},
year = {2025},
doi = {10.1111/bcpt.70000}
}
EUVIMED